By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 5/24/2016 10:59:01 AM
Ipsen (IPN.PA) Partners With Institute of Molecular and Cell Biology To Advance Understanding And Research Of Botulinum Neurotoxin Biology 5/16/2016 9:22:43 AM
Oncodesign SA And Ipsen (IPN.PA) Enter Into A Strategic Partnership In Oncology And Oncodesign Joins Ipsen’s Paris-Saclay Campus 5/3/2016 9:41:41 AM
Ipsen (IPN.PA)’s First Quarter 2016 Sales 4/28/2016 10:39:46 AM
Ipsen (IPN.PA) Is Pleased To Announce That Its Partner Exelixis (EXEL) Obtained FDA Approval Of CABOMETYX (Cabozantinib) Tablets For Patients With Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 4/26/2016 12:42:28 PM
Probi And Ipsen (IPN.PA) Sign Extensive Primary Care Distribution Agreement For Probiotic LP299V, Lactobacillus Plantarum 299v 4/26/2016 12:40:53 PM
Carcinoid Cancer Foundation And Self Care Catalysts Inc. To Provide A Free Digital Patient Support Application For Carcinoid And Neuroendocrine Tumor (NET) Patients, Sponsored In Part By Ipsen (IPN.PA) 4/6/2016 8:08:18 AM
Dassault Systèmes And Ipsen (IPN.PA) Sign Collaborative Agreement To Develop Innovative Programs To Support Ipsen’s Drug Discovery 4/5/2016 10:50:03 AM
Ipsen (IPN.PA) And PeptiMimesis Announce A Research Partnership In Oncology 3/8/2016 1:14:02 PM
Ipsen (IPN.PA)’s 2015 Results And 2016 Financial Objectives 3/1/2016 12:01:42 PM